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It is appealing to believe that better understanding of the 
specific pathophysiology of a disease entity allows the de•
sign or selection of more specific and better therapy. In 
many instances. however, it is obvious that empiric or non•
specific therapy, or both, is very effective, irrespective of 
our understanding of pathophysiologic mechanisms. Va•
sospastic angina is such an instance, since therapy utilizing 
nitrates and calcium channel blocking agents. with their 
potent action on vascular smooth muscle. is usually effec•
tive. Our understanding of the pathophysiology of this dis•
order continues to lag behind therapeutic advances and, 
insofar as it has progressed. has done so largely through 
negative trials. 
The report by Yui et al. (1) in this issue of JACC ad•
dresses the hypothesis that thromboxane A2 is causal in 
vasospastic angina. Previous studies (2·_·5) attempting to 
answer this question have utilized a variety of methods. 
These have included both intravenous and coronary sinus 
sampling of thromboxane B~ and therapeutic trials using 
moderate-dose aspirin as a nonspecific cyclooxygenase in•
hibitor (4.5). The effectiveness of aspirin in inhibiting 
thromboxane Al production has been defined by demon•
strating a decrease in urinary 2,3-dinor thromboxane B2 
excretion (4). These studies have suggested that thrombox•
ane A2 is unimportant in initiating vasospastic angina. The 
hypothesis that a thromboxane Arprostacyclin "imbal•
ance" may play an essential role has been difficult to dispel 
despite evidence that prostacyclin infusion is ineffective in 
most patients with vasospastic angina (6). 
Methodologic issues. In the study of Yui et aI.. a 
well designed experimental protocol was used to evaluate 
patients with clearly documented vasospastic angina. The 
use of a placebo-controlled design allows for easier inter•
pretation of the therapeutic results and is a strong study 
feature. On the other hand. the difficulties in interpreting 
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biochemical data purporting to implicate prostanoids in this 
clinical syndrome are subi'ttantial. These relate both to the 
inherent characteristics of the system being monitored and 
to the methods available for measurement, with this com 
bination resulting in a Heisenberg-like effect. To determine 
the contribution of a potential mediator of coronary spasm. 
it would be desirable to measure the mediator near the active 
site in the coronary circulation. that is, in the coronary 
artery. to avoid dilutional effects and artifacts. With current 
methods the coronary sinus is the closest practical site, and 
blood must be sampled through long catheters; this invar•
iably results in some activation of platelets. The capacity 
to generate thromboxane B2 in serum is approximately 300 
to 400 ng/ml. so that activation of platelets to less than 0, 1 % 
of their capacity during catheter passage would account for 
virtually all of the baseline endogenous thromboxane B2 
levels found in the studies described here. A closer estitnate 
of endogenous thromboxane B2 plasma concentration would 
probably be about I to 2 pg/ml (7). Even allowing for the 
artifactual elevation produced by sampling and despite the 
increase in thromboxane B2 during ischemic attacks. these 
high baseline levels make thromboxane data difficult to in•
terpret As Yui et aL point out. an increase in thromboxane 
B2 with ischemia does not establish a causal role. The po•
tential difficultie5. in defining pathophysiologic mechanisms 
by studYll1g induced rather than spontaneous episodes of 
vasospastic angma should also be appreciated. 
Additional problems in evaluating therapeutic 
trials. Thromboxane A2 might contribute to coronary vaso•
spasm in at least two ways. It is a potent vasoconstrictor. 
and its pre~ence might potentiate epicardial or arteriolar 
vasoconstriclIon. In addition. thromboxane-dependent platelet 
activation might compromise coronary flow in and of itself. 
There is evidence both in vitro and ex vivo that only 5 to 
I O~ 01 the normal capacity to generate thromboxane A2 is 
needed to sustall1 thromboxane-dependent platelet activation 
(8.9). If one assumes that the levels of plasma thromboxane 
B2 described in thIS report are not endogenous baseline 
levels but rather a measure of the capacity to produce throm•
boxane, it would appear that OKY·046, the specific throm•
boxane synthase inhibItor utilized, inhibited thromboxane 
Az formatIOn by 75 to 80%. Thus, thromboxane-dependent 
platelet activation might be expected to continue. Although 
a higher dose of OKY-046 might further decrease the ca•
pacity for production of thromboxane B2• the lack of ther•
apeutic effect 'iccn in studies employing prostacyclin infu•
sions may have answered this question for most patients 
with coronary spasm. A subset of patients for whom ma•
nipulation of prostanoids could be important may still exist. 
Although specific thromboxane synthase inhibition does ap•
pear to increase prostacyclin production. as with throm-
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boxane B2 there are important disadvantages associated with 
the measurement of serum 6-keto-prostaglandin Flu by ra•
dioimmunoassay, even utilizing highly sensitive and specific 
antibodies (9). The authors avoided one potential problem, 
the elevation of prostaglandin 12 production due to intra•
venous or intraarterial catheter placement (1), by not uti•
lizing samples collected at catheterization for these studies. 
Research implications. Despite difficulties inherent in 
exploring the mechanism or mechanisms in vasospastic an•
gina, this report confirms and extends observations sug•
gesting that thromboxane A2 is not likely to be responsible 
for the initiation of ischemic episodes in this syndrome. 
Multiple studies during the past decade have approached 
the problem of coronary vasospasm by attempting to find a 
specific mediator that could explain this clinical syndrome. 
There is now a sizable body of data suggesting that this 
approach, which seemed so rational, may need modifica•
tion. The responsiveness of coronary arteries in patients with 
variant angina to multiple provocative stimuli and the focal 
nature of coronary spasm suggest that a segmental abnor•
mality of the coronary vasculature causes a heightened sen•
sitivity. Several animal models 02,13) suggest that this 
abnormality is in all probability related to the development 
of atherosclerosis. The role of endothelial injury or dys•
function, or both, in this process may be pivotal. It is clear 
that the endothelium is an extraordinarily active and com•
plex tissue, and its role in altering the effect of vasoactive 
agents is currently being defined 04.15). The particular 
stimulus-producing spasm in any given patient may vary 
from time to time and it is possible that multiple circulating 
or locally produced mediators, possibly interacting with or 
modulated by the presence or absence of one or more endo•
thelial factors, are important. Although further clinical stud•
ies with specific inhibitors may provide useful information, 
it is likely that the essential pieces of this puzzle will come 
from a more basic understanding of the pathophysiology of 
these "hyperreactive" arterial segments. 
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